Praxis touts topline data for epilepsy drug in first of four readouts
In January, Praxis priced a $150 million public stock offering and promised four data readouts. And on Tuesday morning, the first topline data dropped in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
